There are currently 183 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
NCT06910124
Recruiting
The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) status. For participants that start the study with residual multiple myeloma cells in participants' bodies: to determine how long you remain MRD-. 2. Increase the length of time that participants' disease... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/11/2025
Locations: University of Miami, Miami, Florida
Conditions: Multiple Myeloma
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. ABBV-453 is an investigational drug being developed for the treatment of R/R MM. In Substudy 1 there will be a dose escalation phase where participants will receive va... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Northwest Medical Specialties Tacoma /ID# 272506, Tacoma, Washington +10 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
NCT07105059
Recruiting
The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Multiple Myeloma
Register for Updates
Elranatamab in R/R Multiple Myeloma
NCT06138275
Recruiting
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Register for Updates
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT06348108
Recruiting
This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). There is currently a significant unmet need for patients with relapsed or refractory multiple myeloma (RRMM) who are triple class refractory and have been exposed to B-cell maturation antibody (BCMA) tar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of Calfornia, San Francisco, San Francisco, California
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Register for Updates
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
NCT06572605
Recruiting
This phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple myeloma patients with extramedullary disease. Extramedullary disease in multiple myeloma involves the infiltration of organs and soft tissues by malignant plasma cells and has proven difficult to treat. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Extramedullary Disease in Multiple Myeloma, Multiple Myeloma
Register for Updates
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101
Recruiting
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: GSK Investigational Site, Mobile, Alabama +76 locations
Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma
Register for Updates
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +31 locations
Conditions: Multiple Myeloma
Register for Updates
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
NCT02682667
Recruiting
Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective: To better understand the biology of malignancies and why certain cancers respond differently to treatment. Eligibility: Adults at least 18 years old with cancer or a pre-cancerous condition. De... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer
Register for Updates
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
NCT05344833
Recruiting
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Myeloma
Register for Updates
64Cu-LLP2A for Imaging Hematologic Malignancies
NCT06636175
Recruiting
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with nega... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Register for Updates
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Recruiting
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Scripps Clinic Torrey Pines, San Diego, California +41 locations
Conditions: Multiple Myeloma
Register for Updates